An insight into the diagnostic and prognostic value of HOX A13's expression in non-muscle invasive bladder cancer.
HOXA13
PPI
bladder cancer
diagnosis
prognosis
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
23
05
2022
received:
28
01
2022
accepted:
14
06
2022
pubmed:
20
7
2022
medline:
14
9
2022
entrez:
19
7
2022
Statut:
ppublish
Résumé
Several studies have interrogated the molecular pathways and their interacting genes underlying bladder cancer (BCa) tumorigenesis, yet, the role of homeobox genes is still poorly understood. Specifically, HOXA13, which plays an important role as a major actor in the urogenital tract's development. Immunohistochemical (IHC) staining was performed to inspect the differential expression of HOXA13 protein in non-muscle-invasive bladder cancer (NMIBC) and non-tumoral tissues. A semiquantitative scoring system was adopted to evaluate the IHC labeling. Correlation to clinical parameters was performed by descriptive statistics. Overall survival was estimated by the Kaplan-Meier method and Cox regression model. The functional HOX A13 protein association networks (PPI) were obtained using String 11.0 database. HOX A13 exhibited cytoplasmic and nuclear staining. Its expression levels were lower in high-grade NMIBC (HG NMIBC) compared to low-grade ones (LG NMIBC). The expression of HOX A13 was correlated to tumor grade (LG/HG) (p = 0.036) and stage (TA/T1) (p = 0.036). Nevertheless, its expression was not correlated to clinical parameters and was not able to predict the overall survival of patients with HG NMIBC. Finally, PPI analysis revealed that HOX A13 seems to be a part of a molecular network holding mainly PBX1, MEIS, ALDH1A2, HOX A10, and HOX A11. The deregulation of HOX A13 is not associated with the prognosis of BCa. It seems to be rather implicated in the early initiation of urothelial tumorigenesis and thus may serve as a diagnostic marker in patients with NMIBC. Further experimentations on larger validation sets are mandatory.
Sections du résumé
BACKGROUND
BACKGROUND
Several studies have interrogated the molecular pathways and their interacting genes underlying bladder cancer (BCa) tumorigenesis, yet, the role of homeobox genes is still poorly understood. Specifically, HOXA13, which plays an important role as a major actor in the urogenital tract's development.
METHODS
METHODS
Immunohistochemical (IHC) staining was performed to inspect the differential expression of HOXA13 protein in non-muscle-invasive bladder cancer (NMIBC) and non-tumoral tissues. A semiquantitative scoring system was adopted to evaluate the IHC labeling. Correlation to clinical parameters was performed by descriptive statistics. Overall survival was estimated by the Kaplan-Meier method and Cox regression model. The functional HOX A13 protein association networks (PPI) were obtained using String 11.0 database.
RESULTS
RESULTS
HOX A13 exhibited cytoplasmic and nuclear staining. Its expression levels were lower in high-grade NMIBC (HG NMIBC) compared to low-grade ones (LG NMIBC). The expression of HOX A13 was correlated to tumor grade (LG/HG) (p = 0.036) and stage (TA/T1) (p = 0.036). Nevertheless, its expression was not correlated to clinical parameters and was not able to predict the overall survival of patients with HG NMIBC. Finally, PPI analysis revealed that HOX A13 seems to be a part of a molecular network holding mainly PBX1, MEIS, ALDH1A2, HOX A10, and HOX A11.
CONCLUSION
CONCLUSIONS
The deregulation of HOX A13 is not associated with the prognosis of BCa. It seems to be rather implicated in the early initiation of urothelial tumorigenesis and thus may serve as a diagnostic marker in patients with NMIBC. Further experimentations on larger validation sets are mandatory.
Identifiants
pubmed: 35853090
doi: 10.1002/jcla.24606
pmc: PMC9459288
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24606Informations de copyright
© 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Tumour Biol. 2020 May;42(5):1010428320918050
pubmed: 32456563
J Hematol Oncol. 2018 Feb 23;11(1):26
pubmed: 29471853
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Sci Rep. 2020 Oct 6;10(1):16641
pubmed: 33024200
Dig Dis Sci. 2014 Jul;59(7):1442-51
pubmed: 24464212
Clin Chim Acta. 2018 Aug;483:64-68
pubmed: 29678634
Med Oncol. 2013;30(2):564
pubmed: 23592225
Int J Cancer. 2012 Aug 1;131(3):E179-89
pubmed: 22020899
Turk J Biol. 2020 Dec 14;44(6):328-355
pubmed: 33402862
Mol Med Rep. 2012 Apr;5(4):901-4
pubmed: 22293681
Cancers (Basel). 2019 May 20;11(5):
pubmed: 31137568
J Mol Med (Berl). 2014 Aug;92(8):811-23
pubmed: 24996520
Int J Cancer. 2016 Oct 1;139(7):1608-17
pubmed: 27225067
Indian J Urol. 2015 Oct-Dec;31(4):289-96
pubmed: 26604439
J Clin Lab Anal. 2022 Sep;36(9):e24606
pubmed: 35853090
J Biochem. 2005 Jun;137(6):671-6
pubmed: 16002988
Sci Rep. 2017 Jul 17;7(1):5619
pubmed: 28717125
Am J Cancer Res. 2015 Sep 15;5(10):3042-55
pubmed: 26693058
World J Surg Oncol. 2018 Jun 18;16(1):109
pubmed: 29914539
Clin Cancer Res. 2008 Feb 1;14(3):742-9
pubmed: 18245534
Int J Cancer. 2009 Oct 1;125(7):1532-41
pubmed: 19488988
Gut. 2002 Sep;51(3):450-4
pubmed: 12171973
Int J Clin Exp Med. 2015 Mar 15;8(3):3619-28
pubmed: 26064257
J Biol Chem. 2004 Nov 19;279(47):49384-94
pubmed: 15339927
Eur Urol. 2004 Mar;45(3):292-6
pubmed: 15036673
Bioessays. 2017 May;39(5):
pubmed: 28322463
Genomics. 2016 Dec;108(5-6):185-193
pubmed: 27826049
J Transl Med. 2015 Mar 12;13:84
pubmed: 25889214
J Biol Chem. 2011 Jan 28;286(4):3161-76
pubmed: 21087928
BJU Int. 2014 Apr;113(4):535-40
pubmed: 23937390
Wien Klin Wochenschr. 2017 Jun;129(11-12):391-397
pubmed: 27830363
Elife. 2020 Jun 18;9:
pubmed: 32553107
Mol Cell Biol. 1997 Oct;17(10):5679-87
pubmed: 9315626
Development. 2002 Feb;129(3):551-61
pubmed: 11830557
Future Oncol. 2017 Jul;13(17):1505-1516
pubmed: 28766961
Int J Mol Sci. 2013 Nov 01;14(11):21727-40
pubmed: 24189220
Jpn J Clin Oncol. 2013 Nov;43(11):1124-31
pubmed: 23980236
J Urol. 2009 Nov;182(5):2195-203
pubmed: 19758621
Int J Urol. 2018 Mar;25(3):212-218
pubmed: 29247553